Amphastar Pharmaceuticals (FRA:29A) Change In Receivables : €-5.7 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals Change In Receivables?

Amphastar Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2025 was €-7.5 Mil. It means Amphastar Pharmaceuticals's Accounts Receivable increased by €7.5 Mil from Dec. 2024 to Mar. 2025 .

Amphastar Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2024 was €-20.7 Mil. It means Amphastar Pharmaceuticals's Accounts Receivable increased by €20.7 Mil from Dec. 2023 to Dec. 2024 .

Amphastar Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2025 was €133.8 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Amphastar Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2025 was 77.40.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Amphastar Pharmaceuticals's liquidation value for the three months ended in Mar. 2025 was €-404.1 Mil.

Amphastar Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Amphastar Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Change In Receivables Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-16.57

-13.21

-9.57

-23.92

-20.70

Amphastar Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-21.35	6.21	-7.26	2.78	-7.47

Amphastar Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.7 Mil.

Amphastar Pharmaceuticals (FRA:29A) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Amphastar Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	133.788	/	157.738	*	91
=	77.40

2. In Ben Graham's calculation of liquidation value, Amphastar Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Amphastar Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	219.117	-	809.369	+	0.75 * 133.788	+	0.5 * 171.565
=	-404.1

Amphastar Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AMPH:USA

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

https://www.amphastar.com

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals Headlines

No Headlines